Reported 13 days ago
Novo Nordisk's CEO Lars Jørgensen was questioned by a Senate committee regarding the high costs of GLP-1 drugs, Wegovy and Ozempic, which are priced at $1,349 and $968, respectively. Despite the drugs generating $50 billion in revenue this year, Jørgensen expressed willingness to negotiate prices with pharmacy benefit managers to increase accessibility. Lawmakers, including Senator Bernie Sanders, criticized the company's pricing tactics, highlighting significant price disparities compared to other countries. Jørgensen insisted that research costs and rebates to pharmacy benefit managers play a significant role in their pricing strategy.
Source: YAHOO